Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
Galapagos NV - American Depositary Shares (GLPG)
Last galapagos nv - american depositary shares earnings: 10/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
glpg.com/company-overview
Company Research
Source: GlobeNewswire
Mechelen, Belgium and Planegg/Munich, Germany; 23 April 2019; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Novartis Pharma AG (SIX: NOVN-CH) announced today the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis. The GECKO trial aims to randomize 60 patients who receive either a dose of MOR106 or placebo subcutaneously for 8 weeks, together with topical steroids, with a 16 week follow-up period. The primary endpoint of GECKO is the incidence of treatment emergent adverse and serious adverse events through day 169. Pharmacokinetics (PK) and occurrence of anti-drug-antibodies after subcutaneous administration of MOR106 will be assessed as secondary endpoints. In addition, the efficacy of MOR106 will be explored. Recruitment will take place in the U.S. and Canada, and the
Show less
Read more
Impact Snapshot
Event Time:
GLPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLPG alerts
High impacting Galapagos NV - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GLPG
News
- Galapagos NV (NASDAQ: GLPG) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $38.00 price target on the stock.MarketBeat
- Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 [Yahoo! Finance]Yahoo! Finance
- Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024GlobeNewswire
- Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings [Yahoo! Finance]Yahoo! Finance
- Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsGlobeNewswire
GLPG
Earnings
- 5/4/23 - Beat
GLPG
Sec Filings
- 4/8/24 - Form 6-K
- 3/29/24 - Form 6-K
- 3/29/24 - Form 6-K
- GLPG's page on the SEC website